Roche Holding AG earnings date
Roche Holding AG (RHOA) Q2 2026 Earnings Report
DE:RHOA Q2 2026 EPS Results
- Actual EPS
- EUR 11.77
- Consensus EPS
- EUR 11.20
- Beat/Miss
- Beat by +EUR 0.56
- One Year Ago EPS
- EUR 12.02
DE:RHOA Q2 2026 Revenue Results
- Actual Revenue
- EUR 32.93B
- Expected Revenue
- EUR 16.87B
- Beat/Miss
- Beat by +EUR 16.06B
- YoY Revenue Growth
- -1.87%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 07/23/2026
- Time
- Before Open
- Conference Call
- Thursday, July 23, 2026
Roche Holding AG's next earnings date is estimated for January 28, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call conveyed strong operational and financial momentum (core operating profit +10%, margin expansion, robust cash flow) combined with substantial pipeline and regulatory momentum (5 FDA priority reviews, 80% Phase III success YTD, multiple product launches/CE marks, and strategic diagnostics M&A). Headwinds were acknowledged and specific: China diagnostics pricing reform, weaker respiratory season, currency translation effects, net debt increase from dividends/timing, competitive pressures (biosimilars) and some impairments. Overall, the positive operational and pipeline developments materially outweigh the challenges, and management maintained confident guidance (mid-single-digit sales growth, high-single-digit core EPS growth) while flagging manageable near-term risks.
Roche stuck to its 2026 guidance: mid‑single‑digit sales growth (group H1 at 6%), high‑single‑digit core EPS growth (core EPS +9% in H1) and a further dividend increase in CHF; management reiterated an expected LOE headwind of roughly CHF 600m for 2026. H1 showed core operating profit +10% (core operating margin +1.7pp), pharma +6% and diagnostics +3% (diagnostics +6% ex‑China; China -15%), with a flu‑season impact of >CHF200m (~1%). Cash metrics were strong: operating free cash flow +21% (+2% in CHF), free cash flow +58% (+26% in CHF), while net debt rose CHF 5.9bn (gross debt ~CHF31.8bn). Diagnostics reaffirmed a 2026 ambition to keep margins broadly stable (~14.4% FY25 level) while targeting mid‑single‑digit sales growth and mid‑ to high‑single‑digit growth in 2027; management also flagged currency headwinds (~‑4 to ‑6 ppts on FY sales/OP/EPS) and a core tax rate of 17.5% in H1, expected to be around 20% for the full year, and said other revenue is expected to rise from ~3% to ~5% of sales by the end of the decade.
- Strong Profitability ExpansionCore operating profit increased +10% (CER) and core operating margin expanded by +1.7 percentage points; core EPS grew +9% — demonstrating margin expansion ahead of sales growth.
- Solid Sales Growth at Constant Exchange RatesGroup sales growth reported at +6% (pharma +6% CER; diagnostics +3% CER); pharma sales reached CHF 23.6 billion (6% CER, 8% in USD, -1% in CHF).
- Robust Cash Flow GenerationOperating free cash flow increased +21% (plus +2% in CHF) and free cash flow rose +58% (timing effects noted); strong cash generation underpins dividend increase and reinvestment.
- Significant Pipeline and Regulatory MomentumFive U.S. FDA priority reviews granted year-to-date; Phase III success rate reported at 80% YTD with two positive Phase III readouts in the quarter; multiple filings and near-term readouts expected (several Phase III events and NMEs planned).
- Notable Clinical Wins — Oncology and HematologyPositive Phase III KRASCENDO-1 (divarasib) showed superiority vs approved G12C inhibitors with PFS and OS improvements (OS reached statistical significance at interim); hematology franchise grew +14% CER driven by Hemlibra and Polivy uptake.
- Diagnostics Product and M&A ProgressAXELIOS 1 sequencing solution launched (June 29) leveraging SBX chemistry; CE marks/launches for Elecsys pTau217 (Alzheimer’s) and Elecsys IGRA TB test; completed strategic acquisition of PathAI to augment digital pathology capabilities.
- Obesity/CVRM Portfolio AdvancementPositive Phase II data for petrelintide (placebo-like tolerability) and enicepatide (48% of patients achieved >20% weight loss; 26% achieved >30% at highest dose); petrelintide Phase III decision taken and Phase III starts planned H2.
- Lower-than-anticipated LOE ImpactLoss-of-exclusivity (LOE) impact in H1 was CHF 244 million and the company now expects LOE impact of roughly CHF 600 million for 2026 — a smaller headwind than earlier guidance.
DE:RHOA Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Jan 28, 2027 | 2026 (Q4) | 10.52- | 9.08 | ― | ― |
| Jul 23, 2026 | 2026 (Q2) | 11.2011.77 | 12.02 | -2.08% (-0.25) | |
| Jan 29, 2026 | 2025 (Q4) | 9.249.08 | 9.3 | -2.28% (-0.21) | |
| Jul 24, 2025 | 2025 (Q2) | 11.6812.02 | 11.1 | 8.31% (+0.92) | |
| Jan 30, 2025 | 2024 (Q4) | 8.819.30 | 9.19 | 1.18% (+0.11) | |
| Jul 25, 2024 | 2024 (Q2) | 10.1611.10 | 37.69 | -70.56% (-26.59) | |
| Feb 01, 2024 | 2023 (Q4) | 9.089.19 | 8.97 | 2.42% (+0.22) | |
| Jul 27, 2023 | 2023 (Q2) | 11.0137.69 | 12.76 | 195.46% (+24.93) | |
| Feb 02, 2023 | 2022 (Q4) | 9.378.97 | 10.03 | -10.59% (-1.06) | |
| Jul 21, 2022 | 2022 (Q2) | 9.9212.76 | 11.45 | 11.36% (+1.30) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


